Dallas, Texas (PRWEB) June 13, 2013

Sales (number) of iPSC research products worldwide have been growing at a rate of 14.7% per year for the past five years. In addition, 22% of all stem cell researchers now self-report as having used induced pluripotent stem cells within a research project. It is clear that iPSCs are a vital research trend within the scientific community. A distinctive feature of this report is an end-user survey of 293 researchers (181 U.S. / 112 International) that identify as having induced pluripotent stem cells as their core research focus. These survey findings reveal iPSC researcher needs, technical preferences, key factors influencing buying decisions, and more. They can be used to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

Complete 2012-13 Induced Pluripotent Stem Cell Industry Report on market metrics, dynamics, and trends says continued research and experimentation has resulted in numerous advances over the last few years. In one example, the University of Michigan announced in Circulation Research (2012) that they had developed innovative methods for use of induced pluripotent stem cells derived from skin biopsies to create cardiac muscle cells. This accomplishment quickly fueled other research into the use of iPSCs for the reversal and repair of diseased heart tissue. Similar advances will continue to be perfected for use of reprogrammed adult cells in the treatment of other diseases and disorders. Original techniques for iPSC production, such as viral induced transcription processes, are being replaced with newer technologies as private industries join with the scientific community to develop safe and efficient methods of iPSC production. With sustained research and experimentation, established guidelines for effective production of iPSC will be commonplace.

In summary, induced pluripotent stem cells represent a promising tool for use in the reversal and repair of many previously incurable diseases. This is a must-read industry report for research supply companies to optimally position themselves to sell iPSC products. To profit from this lucrative and rapidly expanding market, one needs to understand ones key strengths relative to the competition, intelligently position own products to fill gaps in the market place, and take advantage of the crucial iPSC trends. Claim this report now to profit from this expanding market - Buy / Order a copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=206575.

Key findings of this report on iPSC market include:

Companies and Research Institutes mentioned / covered in this report:

Commerical entities developing iPSC therapies: ViaCyte, Fate Therapeutic, iPerian, Cellular Dynamics and Mesoblast.

Strategic collaborations for development of iPSC products: Life Technologies, Lonza Group AG, EMD Millipore, Sigma Aldrich, Roslin Cells, Ltd., ArunA Biomedical, CeeTox and Cellular Dynamics.

Top research institutions performing stem cell research: University of Wisconsin, including WARF, WiCell, and the WISC Bank, US National Institutes of Health (NIH), Johns Hopkins University, California Institute for Regenerative Medicine and University of Connecticut Induced Pluripotent Stem Cell Core (iPSCC).

Comprehensive Table of Contents and more on the report Complete 2012-13 Induced Pluripotent Stem Cell Industry Report on Market Metrics, Dynamics, and Trends @ http://www.reportsnreports.com/reports/206575-complete-2012-13-induced-pluripotent-stem-cell-industry-report.html.

See more here:
Induced Pluripotent Stem Cell Industry (iPSC Market) Report Updated for 2013 Now Available at ReportsnReports.com